Which CGRP ligand-targeting monoclonal antibody is used for migraine prevention?

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

Multiple Choice

Which CGRP ligand-targeting monoclonal antibody is used for migraine prevention?

Blocking CGRP signaling for migraine prevention can be achieved by either targeting the CGRP ligand or the CGRP receptor. The ligand-targeting monoclonal antibody binds the CGRP peptide itself, preventing it from activating its receptor and thereby reducing migraine frequency. Fremanezumab fits this mechanism by binding CGRP ligand and lowering the signaling that drives migraine attacks. In contrast, the monoclonal antibody that targets the receptor would block the receptor itself rather than the ligand. The other two options are small-molecule CGRP receptor antagonists (gepants) used for acute treatment, not preventive therapy, and they are not monoclonal antibodies. Hence, Fremanezumab is the ligand-targeting antibody used for migraine prevention.

Blocking CGRP signaling for migraine prevention can be achieved by either targeting the CGRP ligand or the CGRP receptor. The ligand-targeting monoclonal antibody binds the CGRP peptide itself, preventing it from activating its receptor and thereby reducing migraine frequency. Fremanezumab fits this mechanism by binding CGRP ligand and lowering the signaling that drives migraine attacks.

In contrast, the monoclonal antibody that targets the receptor would block the receptor itself rather than the ligand. The other two options are small-molecule CGRP receptor antagonists (gepants) used for acute treatment, not preventive therapy, and they are not monoclonal antibodies. Hence, Fremanezumab is the ligand-targeting antibody used for migraine prevention.

More practice questions